Ironwood Pharma (IRWD) Tops Q1 EPS by 3c, Revenues Miss; Offers FY21 Revenues Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
May 6, 2021 7:03 AM EDTBOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $150 million of its outstanding shares of common stock through December 2022.
Ironwood maintains a disciplined and thoughtful... More
Ironwood Pharmaceuticals Reports First Quarter 2021 Results
May 6, 2021 7:00 AM EDTLINZESS® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year
Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million
GAAP net income of $40 million and adjusted EBITDA of $46 million; ended Q1 2021 with $438 million in cash and cash equivalents
Maintaining full year 2021 financial guidance
BOSTON--(BUSINESS... More
